Summary & Overview
CPT 53852: Radiofrequency Ablation of Prostatic Tissue for BPH
CPT code 53852 denotes radiofrequency ablation of prostatic tissue for the treatment of benign prostatic hypertrophy (BPH). This code captures a minimally invasive surgical approach intended to reduce obstructive prostatic tissue and relieve lower urinary tract symptoms in male patients. Nationally, procedures coded with 53852 are relevant to urology practice patterns, outpatient surgical volumes, and payer coverage policies for newer minimally invasive BPH therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical indication for the code, typical sites of service, and common billing context. The publication summarizes benchmark payment and utilization considerations, highlights relevant policy and coverage updates affecting adoption of ablative therapies for BPH, and places the procedure in clinical context relative to other surgical and office-based BPH treatments.
This resource is intended for billing managers, practice administrators, and policy analysts seeking a clear statement of what CPT code 53852 represents, how it is typically delivered, and what national payers consider when assessing coverage and payment for radiofrequency ablation of the prostate.
Billing Code Overview
CPT code 53852 describes a procedure in which the provider destroys prostatic tissue using radiofrequency ablation to treat benign prostatic hypertrophy (BPH) in male patients. This is a minimally invasive surgical therapy aimed at reducing obstructive prostatic tissue to improve urinary flow and relieve lower urinary tract symptoms associated with BPH.
Service Type: Radiofrequency ablation of prostatic tissue (minimally invasive surgical therapy)
Typical Site of Service: Ambulatory surgery center or hospital outpatient setting, depending on patient comorbidities and facility capabilities.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with symptomatic benign prostatic hyperplasia presents with progressive lower urinary tract symptoms (weak urinary stream, nocturia, incomplete bladder emptying) refractory to medical therapy with alpha-blockers and 5-alpha-reductase inhibitors. After urologic evaluation including digital rectal exam, prostate-specific antigen testing, and transrectal ultrasound estimating prostate volume of 40–80 g, the patient elects minimally invasive prostate tissue ablation using radiofrequency energy. The procedure is performed in an outpatient ambulatory surgery center under monitored anesthesia care. The urologist—typically board-certified in urology—uses a transurethral radiofrequency ablation device to destroy targeted prostatic tissue to relieve bladder outlet obstruction. Typical workflow: pre-procedure evaluation and informed consent, perioperative antibiotics as indicated, anesthesia induction, cystoscopic or transurethral device placement, radiofrequency ablation delivered to planned tissue zones, intraoperative hemostasis and catheter placement as needed, recovery with short observation, discharge with catheter care instructions and scheduled follow-up to assess voiding and potential complications such as urinary retention, hematuria, infection, or urinary incontinence.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting only the physician’s professional component separate from technical services. |